Clinical Trial Update: A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetics study evaluated the effect of vemurafenib on digoxin exposure in patients with BRAFV600 mutation-positive metastatic melanoma; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• DIGOXIN (Digoxin)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma, Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2015-08-10